PharmaCyte Biotech, Inc.
PMCBNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$4.4M | −$8.5M | −$6.5M | −$4.4M | −$3.6M | −$3.8M |
| Net income | $30.7M | $333,763 | −$4.3M | −$4.2M | −$3.6M | −$3.8M |
| Total assets | $55.2M | $59.9M | $73.3M | $90.6M | $7.4M | $6.2M |
| Total liabilities | $3.3M | $20.4M | $586,581 | $704,370 | $724,778 | $1.1M |
| Equity | $51.9M | $27.6M | $72.7M | $89.9M | $6.7M | $5.1M |
| EPS (diluted) | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.45 | — |
| Shares out. | 6.8M | 7.7M | 8.8M | 20.7M | 1.6M | 2.33B |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 59.1%
- Return on assets
- 55.6%
- Return on capital (ROCE)
- −8.4%
- Liabilities / assets
- 5.9%
- Debt / equity
- 0.06×
- Book value / share
- $7.64
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- 9085.0%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 13.39safe
- Accruals / assets
- 61.0%high accruals
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 3 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Dec 15, 2025
- NT 10-Kmissed a reporting deadline ↗Jul 29, 2025
- NT 10-Qmissed a reporting deadline ↗Sep 17, 2024
- NT 10-Kmissed a reporting deadline ↗Jul 29, 2024
- NT 10-Qmissed a reporting deadline ↗Sep 15, 2023
- NT 10-Kmissed a reporting deadline ↗Jul 29, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Intracoastal Capital, LlcPassive (13G)Feb 13, 2026
- Ayrton Capital LlcPassive (13G)Feb 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Silverman JoshuaOfficer — CEO and President | Jan 5, 2026 | Buy | 30,000 | $0.78 |
| Schechter JonathanDirector | Jan 5, 2026 | Buy | 20,000 | $0.78 |
| Weinstein RobertDirector | Dec 12, 2025 | Grant | 75,000 | $0.00 |
| Walker Wayne RemellDirector | Dec 12, 2025 | Grant | 37,500 | $0.00 |
| Silverman JoshuaOfficer — CEO and President | Dec 12, 2025 | Grant | 575,000 | $0.00 |
| Schechter JonathanDirector | Dec 12, 2025 | Grant | 150,000 | $0.00 |
| Abecassis Michael MDirector | Dec 12, 2025 | Grant | 37,500 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 469,898 | 1.2 | +356.3% |
| Apr 30, 2026 | 102,979 | 1.0 | +21.4% |
| Apr 15, 2026 | 84,833 | 1.0 | -12.9% |
| Mar 31, 2026 | 97,390 | 1.0 | +0.5% |
| Mar 13, 2026 | 96,921 | 1.0 | -8.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteApr 2, 2026
- Delisting / listing-standard noticeDec 5, 2025
- Director / officer change · Shareholder voteOct 31, 2025
- Entered a material agreement · Completed an acquisition or disposition · Regulation FD disclosureSep 5, 2025
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureAug 18, 2025
- Shareholder voteApr 24, 2025
- Changed auditorFeb 26, 2025
- Entered a material agreement · Completed an acquisition or disposition · Other material eventMay 23, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4Apr 2, 2026
- 4Apr 2, 2026
- 4Apr 2, 2026
- 4Apr 2, 2026
- 8-KFORM 8-KApr 2, 2026
- 4Mar 18, 2026
- SCHEDULE 13GMar 18, 2026
- 10-QFORM 10-Q FOR JAN 2026Mar 17, 2026
- ARSANNUAL REPORTMar 9, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTMar 9, 2026
- PRE 14APRELIMINARY PROXY STATEMENTFeb 27, 2026
- SCHEDULE 13G/AFeb 13, 2026
- 4Jan 7, 2026
- 4Jan 7, 2026
- 10-QFORM 10-Q FOR OCT 2025Dec 18, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.